Paysign, Inc. (NASDAQ:PAYS) CFO Sells $215,507.64 in Stock

Key Points

• Paysign, Inc. CFO Jeffery Bradford Baker sold 30,396 shares of the company for approximately $215,507.64, resulting in a 10.75% decrease in his ownership.
• The company's stock price reached $7.16 after gaining $0.02 during trading, with a market cap of $388.22 million and a price-to-earnings ratio of 65.10.
• Paysign reported a $0.05 EPS for the last quarter, exceeding expectations, alongside revenue of $18.60 million, higher than the forecast of $17.49 million.

Paysign, Inc. (NASDAQ:PAYS - Get Free Report) CFO Jeffery Bradford Baker sold 30,396 shares of the stock in a transaction on Monday, August 4th. The stock was sold at an average price of $7.09, for a total value of $215,507.64. Following the transaction, the chief financial officer owned 252,273 shares of the company's stock, valued at $1,788,615.57. This represents a 10.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Paysign Price Performance

Shares of PAYS stock traded up $0.02 during trading hours on Monday, hitting $7.16. 949,589 shares of the company's stock were exchanged, compared to its average volume of 954,471. The stock's 50-day moving average is $6.45 and its 200-day moving average is $3.93. The stock has a market cap of $388.22 million, a price-to-earnings ratio of 65.10 and a beta of 0.78. Paysign, Inc. has a 52 week low of $1.80 and a 52 week high of $8.88.

Paysign (NASDAQ:PAYS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.01. The business had revenue of $18.60 million for the quarter, compared to analysts' expectations of $17.49 million. Paysign had a return on equity of 19.49% and a net margin of 9.55%. Equities research analysts forecast that Paysign, Inc. will post 0.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on PAYS. LADENBURG THALM/SH SH increased their price objective on Paysign from $7.25 to $8.25 and gave the stock a "buy" rating in a research note on Friday, May 9th. DA Davidson set a $8.00 price objective on Paysign in a research note on Friday, June 13th. Finally, Lake Street Capital increased their price objective on Paysign from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th.

Hedge Funds Weigh In On Paysign

Hedge funds have recently added to or reduced their stakes in the company. PDT Partners LLC acquired a new position in Paysign in the fourth quarter valued at about $39,000. Royce & Associates LP lifted its stake in Paysign by 36.5% in the first quarter. Royce & Associates LP now owns 19,319 shares of the company's stock valued at $41,000 after buying an additional 5,166 shares during the period. Wells Fargo & Company MN raised its position in shares of Paysign by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 15,385 shares of the company's stock worth $46,000 after purchasing an additional 5,243 shares during the period. Jane Street Group LLC acquired a new stake in shares of Paysign during the first quarter worth about $51,000. Finally, Occudo Quantitative Strategies LP raised its position in shares of Paysign by 56.5% during the fourth quarter. Occudo Quantitative Strategies LP now owns 28,429 shares of the company's stock worth $86,000 after purchasing an additional 10,268 shares during the period. Institutional investors own 25.89% of the company's stock.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.